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INTRODUCTION
The oral cavity is inhabited by diverse microbiota that plays
an important role in maintaining oral and systemic health (1).
The presence of oral commensals inhibits colonization by
pathogens by occupying the binding sites on oral surfaces (2).
Salivary glycoproteins selectively absorbed on teeth form a
pellicle. Salivary pellicle provides an attachment surface to
primary colonizer oral bacteria (3, 4). Other bacteria will then
co-aggregate with the primary colonizers via coaggregation
interactions (5). The result is a dental plaque, but its formation
can be kept to a minimum by regular tooth cleaning. When oral
hygiene is poor, the proportion of Gram-negatives and anaerobic
species increases in the maturing plaque, and the presence of
endotoxin and other bacterial products leads to periodontal
disease (1). Periodontal diseases are highly prevalent and can
affect up to 90 percent of the human population worldwide (6).
Their accurate diagnosis can still be a challenge (7). In essence,
periodontal diseases are the pathological manifestation of the
host response against bacterial challenge from dental biofilm at
the tooth/gingival interface (8). The mildest and fully reversible
form of periodontal disease is gingivitis, which does not affect
tooth supporting tissues (9). Untreated gingivitis may advance to
periodontitis over time. Dental plaque formation spreads
apically and the junctional epithelium at the bottom of the
gingival sulcus is destroyed by accumulating bacterial
complexes. The resulting epithelial downgrowth and pocket
formation allows plaque bacteria to colonize subgingival root
surfaces. Toxins from Gram-negative bacteria such as
Porphyromonas gingivalis and Aggregatibacter
actinomycetemcomitans (and a number of other ones) in the
pocket induce an inflammatory host reaction. The subsequent
tissue destruction is driven by mediators of the host immune-
inflammatory response to the infection (9) resulting in increased
pocket depths. At the same time, gingival connective tissue,
Sharpey fibers and alveolar bone are destroyed. Unfortunately,
as the destructive process mostly presents only with very mild
symptoms, the disease remains untreated until teeth lose their
ligamentous connection to the alveolar bone, become mobile and
are eventually lost (10, 11).
Alveolar bone loss and chronic inflammatory process are
important clinical hallmarks of chronic periodontal disease.
Therapeutic intervention should ideally aim at dampening the
inflammatory immune response regenerating the lost
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Periodontitis is a chronic inflammatory disease leading to alveolar bone destruction, and eventually tooth loss. In
genetically or environmentally predisposed individuals periodontopathogenic bacteria trigger an inflammatory immune
response where activated macrophages secrete inflammatory cytokines and T helper 17 cells produce interleukin-17,
receptor activator of nuclear factor kappa B ligand (RANKL) and tumor necrosis factor-a. Inflammation and the
production of RANKL, the key cytokine responsible for osteoclast activation, cause excessive activation of osteoclasts.
This results in a decoupling between bone formation and resorption, leading to bone loss. As conventional treatment
does not target the inflammatory response and osteoclast activation, its effectiveness is limited. Novel treatments are
thus required if we are to cure this disease. Mesenchymal stem cells (MSCs), including those of dental origin, are potent
immunomodulators and are known to be suitable for tissue regeneration. MSCs can inhibit the immune response by
suppressing T cells, inducing regulatory T cells and converting dendritic cells and macrophages into a regulatory
phenotype. Additionally, genetic modulation may enhance the therapeutic potential of MSCs. In the present review the
authors describe the potential use of MSCs, either unmodified or engineered for therapeutic purposes in periodontitis,
with special emphasis on MSCs from dental pulp and periodontal ligament. The paper envisions that multiple targeting
of this inflammatory disease by modulating the immune response, promoting bone regeneration and inhibiting bone
resorption might yield significantly improved treatment outcomes when combined with conventional treatment
modalities.
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anantomical structure and function of the periodontal region as
well as possibly restoring the normal commensal microbiota.
Conventional treatment options include the removal of bacterial
deposits and surgical tissue regeneration procedures in
periodontitis (12). Such treatments also include oral hygiene
instructions and scaling/root planing, aiming to prevent the
disease, slowing down or stopping its progress and maintain the
therapeutic goals achieved. However, such interventions are
usually insufficient to promote the regeneration of damaged
structures (13). Thus, novel treatment modalities such as using
anti-inflammatory substances (14, 15) are required for
successful treatment. One innovative approach, the use of
mesenchymal stem cells (MSCs), offers the possibility to
simultaneously target the inflammatory response and to promote
the regeneration of the periodontal structure. MSCs have been
isolated from a number of adult tissues such as bone marrow,
adipose tissue, gingiva and dental tissues. Adult MSCs are
known to be capable of differentiating into various cell types,
thereby facilitating tissue regeneration after damage due to
injury, inflammation or other pathologies (16, 17). MSCs also
have potent immunomodulatory capabilities via secretion of
regulatory cytokines and other modulatory factors or via direct
cell-cell contact (18, 19). MSCs of dental origin, including
dental pulp stem cells (DPSCs) and periodontal ligament stem
cells (PDLSCs), are of particular interest. Despite their small
size, teeth are an abundant source of DPSCs and PDLSCs (20,
21). Importantly, MSCs are normally obtained from teeth
removed during routine dental care and they can be cultured
under standard conditions (22). Therefore, the process involves
no additional burden on the patient beside from that of routine
tooth extraction. The use of various biomolecules may also help
to reduce the pathological bone loss (23) as well as promote and
support the regenerative processes (24). Several growth factors
such as BMP-2 (25, 26) or bFGF (27) have already been
proposed and tested in animal models for this purpose. The
pharmaceutical targeting of the RANKL/OPG balance to reduce
bone loss in periodontitis has also been introduced and reported
in animal experiments (28).
The aim of this review is to discuss the immunopathome-
chanism of periodontitis and its relation to bone loss, to address
the potential use of mesenchymal stem cells, especially those of
dental origin, either unmodified or engineered to express
biomolecules for therapeutic purposes, to treat this complex
disease.
PATHOLOGICAL BONE LOSS AND
IMMUNOREGULATION IN PERIODONTITIS
A persistent host inflammatory response and the resulting
chronic inflammation is one of the key factors in the destruction
of soft and mineralized periodontal tissues in periodontitis (29).
It is characterized by the destructive activity of multiple
elements of the immune system along with the overactivation of
osteoclasts and diminished osteoblast activity, resulting in an
imbalance in bone formation and breakdown. The process is not
fully understood, but what is known already offers several
potential targets for the treatment of periodontal disease.
A shift in the balance between osteoclast and osteoblast
function in periodontitis
Physiological and pathological bone resorption is carried out
by a specialized cell type called the osteoclasts. Osteoclasts are
hematopoietic lineage derived cells originating from monocytes.
Monocytes are released from the bone marrow into the blood,
where they home into different tissues and differentiate into
tissue-resident macrophages (30). Osteoclasts are formed in
response to appropriate stimuli by the fusion of mononuclear
precursors within the monocyte fraction of peripheral blood.
Macrophage colony stimulating factor (M-CSF) and receptor
activator of NFkB ligand (RANKL) are the two key factors that
drive osteoclast formation and activity (Fig. 1) (31, 32). M-CSF,
produced by osteoblasts or bone marrow stromal cells,
stimulates the expression of RANK (the receptor for RANKL)
on osteoclast precursors, allowing RANKL to drive mature
osteoclast formation (33). Under normal circumstances,
RANKL is expressed on the surface of osteoblasts and
osteocytes (34). Osteoprotegerin (OPG), a soluble decoy
receptor for RANKL, inhibits RANKL-induced osteoclast
formation and activation (Fig. 1) (35, 36). OPG is produced by
human periodontal ligament cells, gingival fibroblasts and
epithelial cells (37, 38). Thus, osteoclast activity depends on the
balance between RANKL and OPG.
Osteoblasts are bone forming cells, which also produce bone
morphogenetic proteins, including BMP-2, which plays a major
role in the differentiation of bone cell lineages, bone
development and bone repair (39). BMP-2 also promotes
RANKL secretion by osteoblasts, and is crucial for osteoclasts
by offering a suitable microenvironment for their differentiation
(40) (Fig. 1). Furthermore, under physiological conditions, they
are the main sources of RANKL and M-CSF for the
development of osteoclasts (40). Bone formation and bone
resorption are thus normally coupled (41, 42). A shift in this
balance toward bone resorption occurs in a number of chronic
inflammatory diseases, which results in bone loss.
As discussed above, osteoclast activity depends on the
RANKL/OPG ratio (23). The main sources of RANKL under
normal circumstances are osteoblasts and osteocytes (34). In
periodontal lesions the excess amounts of RANKL, produced
mostly by activated T and B cells (43), increase the RANKL/OPG
ratio which favors osteoclast activation and bone resorption.
Importantly, RANKL inhibition by OPG blocks bone loss in
experimental periodontitis (28) (Fig. 1). As a prototype of novel
therapeutic approaches, denosumab, a fully human monoclonal
antibody that targets RANKL, i.e. mimics the effect of OPG, is
already in use in humans to prevent bone loss in a number of
diseases including osteoporosis and periodontitis (44).
In summary, bone resorption is mediated by osteoclasts,
whose activity is determined by the RANK/RANKL/OPG axis.
In periodontitis, the development and maintenance of a
pathogenic inflammatory milieu leads to inappropriately high
RANKL levels, excessive osteoclast activation and bone loss.
Therapeutic methods are being developed to inhibit
inflammatory processes and osteoclast function.
The role of dendritic cells
T cell response, a major component of the adaptive immunity,
is induced and controlled by antigen presenting cells (45).
Dendritic cells (DCs) and macrophages are the most important
professional antigen presenting cells. Dendritic cells may be
subdivided into classical DCs (cDCs) and plasmacytoid DCs
(pDCs) (46). cDCs specialize in antigen presentation to T cells
and thereby initiating and controlling immunity (30). They are
characterized by high phagocytic activity as immature cells and
high cytokine producing capacity as mature cells. cDCs are
generally short-lived (30, 47), whereas plasmocytoid DCs
(pDCs) are relatively long-lived (30, 48). pDCs are found both in
bone marrow and in peripheral organs. Besides from controlling
T cell responses, they produce large amounts of type I interferons
in response to viral infection (49). There are conflicting reports
on the presence of DCs in periodontitis lesions and on their role
in the pathogenesis of the disease (50). A recent study by Allam
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and coworkers showed a sharp decrease in the number of CD1a+
DCs in chronic periodontitis lesions compared with healthy oral
mucosa (51).
The role of macrophages
Macrophages eliminate dead cells that underwent apoptosis or
necrosis, produce growth factors and cytokines and act as a first
line of defense against invading bacterial pathogens. They
differentiate from circulating peripheral blood mononuclear cells
that migrate into tissues in steady state or during inflammation
(52). In addition, by presenting antigens, they have a key role in T
cell activation and in the polarization of the adaptive immune
response. Three populations of activated macrophages have been
identified: classically activated, wound healing and regulatory
macrophages (Fig. 1) (53). Classically activated macrophages
function in the defense against intracellular pathogens and secrete
high levels of pro-inflammatory cytokines. However, the
cytokines and mediators they produce, can be harmful to the host:
tumor necrosis factor (TNF)-a, interleukin (IL)-1, IL-6 and IL-23
produced by classically activated macrophages promote the
development and expansion of Th17 cells (53) (Fig. 1). Wound
healing macrophages arise in response to IL-4 or IL-13 and mostly
contribute to the synthesis of extracellular matrix (54). Regulatory
macrophages produce high levels of the immunosuppressive
cytokine IL-10 and downregulate the production of IL-12. Since
IL-10 inhibits the production and counteracts the effects of several
pro-inflammatory cytokines, regulatory macrophages are strong
inhibitors of inflammation (53).
Macrophages were detected in considerable numbers in
inflammatory infiltrates from periodontitis subjects (51, 55). They
play key roles in regulating the immune response in periodontitis
not only by presenting antigens to T cells but also by secreting a
variety of inflammatory cytokines such as IL-1, IL-6 and TNF-a
(56-58), which directly or indirectly influence the differentiation
and function of osteoclasts, the key mediators of bone resorption.
For example, TNF-a secreted by activated macrophages stimulates
osteoclast differentiation both directly (56, 59) and indirectly via
stimulating RANKL production by osteoblasts (60) (Fig. 1).
Furthermore, osteoclasts are derived from the
monocyte/macrophage lineage, and therefore macrophages
themselves can differentiate into new osteoclasts (61). Therefore,
the relationship between monocytes/macrophages and the biology
of osteoclasts is well established.
The role of T cell subsets
T cell differentiation, a key factor in the immune response, is
regulated by antigen presenting cells via the production of
cytokines (62, 63). Naive CD4+ T helper cells may differentiate
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Fig. 1. Immune regulation of osteoclast function in periodontal inflammation. This figure depicts a very complex mechanism that is
presently not fully understood. Osteoclasts are derived from the monocyte/macrophage lineage. Circulating monocytes home to tissues
to become macrophages (MÆ) and, depending on environmental cues, can assume classically activated, wound healing and regulatory
phenotypes. These innate immune cells phagocytose and kill invaders and interact with the components of the adaptive immune system
by presenting antigens and producing cytokines. Key components of the adaptive immune response in periodontitis are CD4+ helper
T cells (Th). Th1, Th2, Th17 and regulatory T cells (Treg) differentiate in response to certain cytokines, some of which are shown in
the figure. Also shown are certain cytokines by which they regulate the differentiation of MÆ subsets and of osteoclasts. Osteoclast
differentiation and function is regulated by the receptor RANK on the surface of osteoclasts and osteoclast precursors. Its activating
ligand is RANKL, most of which is produced by Th17 cells in periodontitis. The effect of RANKL is blocked by its decoy receptor
OPG, produced by bone marrow stromal cells and osteoblasts, the cell type that produces bone and secretes bone morphogenetic
proteins (BMPs), including BMP-2, which is a key morphogen for bone formation, but an osteoclast activator as well. Osteoclast
activity is determined by the ratio of the amounts of RANKL and OPG. In addition to BMP-2 and OPG, osteoblasts also produce
RANKL. Under physiologic conditions, this ensures that the synthesis and the resorption of bone are coupled.
Bold arrows, cell development pathways; dashed arrows, cytokines with a certain effect produced by a cell type; IFN, interferon; TNF,
tumor necrosis factor; TGF, transforming growth factor; BMP, bone morphogenetic protein; RANK, receptor activator of NFkB;
RANKL, RANK Ligand; OPG, osteoprotegerin; IL, interleukin; Th, helper T cell; Treg, regulatory T cell; MÆ, macrophage.
into T helper 1 (Th1), Th2 (64), Th17 (65) and regulatory T
(Treg) (66) cells.
Th1 differentiation is induced by IFN-g and IL-12 (67, 68)
(Fig. 1). Th1 cells are critical in cell-mediated immunity to clear
intracellular pathogens. Th2 cells are induced by IL-4 (Fig. 1) (67).
The Th2 effector cytokines are IL-4, IL-5 and IL-13 (69, 70). ATh2
immune response is more effective against extracellular pathogens.
Th17 cells are a new pathogenic Th cell subpopulation (65,
71) (Fig. 1). These cells play a role in the pathogenesis of several
autoimmune/inflammatory diseases (72-75). In mice, the key
cytokines for Th17 cell differentiation are TGF-b and IL-6/IL-21
(76, 77). IL-23 is required for Th17 cell maintenance and
expansion (78, 79). IL-1b and TNF-a also amplify Th17
development (79, 80). In humans, TGF-b, IL-1b, IL-6, IL-21
and IL-23 are required for Th17 differentiation (81, 82). IL-23 is
secreted by innate immune cells such as DCs and macrophages
in response to stimulation of certain pattern recognition
receptors or other signals (83). IL-23 receptor is expressed on T
cells, natural killer cells, DCs and macrophages (84). The
effector cytokines secreted by Th17 cells are IL-17, IL-17F, IL-
21, IL-22 and IL-9 (85, 86). The amount of IL-17 correlates with
the presence and degree of periodontitis (87). IL-17 and IL-17F
induce the production of proinflammatory cytokines such as
TNF-a, IL-1b, GM-CSF, G-CSF, IL-6 and certain chemokines
(85), whose proinflammatory effects are exerted on a variety of
cell types including fibroblasts, monocytes, macrophages,
epithelial cells and osteoblasts.
Th17 cells have been shown to be involved in periodontitis
(88). IL-17 produced by Th17 cells induces RANKL expression
by osteoblasts, leading to osteoclast stimulation (89, 90) (Fig. 1).
IL-17 also elicits the production of pro-inflammatory cytokines
such as IL-1, IL-6 and TNF-a by fibroblasts, endothelial cells,
macrophages and epithelial cells (91, 92), thus producing and
maintaining an inflammatory milieu. Th17 cells also themselves
express RANKL (89), and TNF-a (93) which induces
osteoclastogenesis on osteoclast precursors in synergy with
RANKL. These characteristics clearly link Th17 cells to sustained
inflammation and pathologic bone loss in periodontal disease.
Regulatory T cells (Treg) modulate the immune response
and inhibit inflammation (94, 95) (Fig. 1). They develop in the
thymus and play an essential role in preventing the inappropriate
activation of the immune system (96). To date, the most specific
marker of Tregs is the transcription factor Foxp3 (97-99).
Secretion of IL-10 and TGF-b is an important aspect of immune
regulation by Treg cells (100).
Tregs are also involved in the regulation of immune response
in periodontitis (Fig. 1). Their presence has been demonstrated
in the periodontal environment (101). In humans P. gingivalis
infection has been shown to be associated with Tregs
dysregulation leading to diminished Treg function (102). In a
mouse model of periodontitis, periodontopathogen infection
increased the number of Treg cells in periodontal tissue (103).
Inhibition of Treg function decreased the production of Treg
signaling molecules IL-10, CTLA-4 and TGF-b, stimulated the
production of the inflammatory cytokines IFN-g, TNF-a and
RANKL, and increased the number of leukocytes and bone loss
in periodontal tissues. This clearly demonstrates that Tregs
attenuate periodontitis (103). This is also supported by a more
recent study that has also demonstrated the induction of IL-10
producing Treg cells in periodontitis (104). Very recent data
indicate that the modulation of the Th17/Treg imbalance by
retinoic acid administration provides protection against
periodontitis by enhancing Treg cell activation and inhibiting
Th17 cell activation, suggesting the potential for clinical
prevention of periodontitis (105).
MESENCHYMAL STEM CELL THERAPY
FOR PERIODONTITIS
Mesenchymal stem cells (MSCs) are a class of multipotent
cells originally identified in bone marrow (106, 107). Their high
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Fig. 2. Multiple ways of immunoregulation by mesenchymal stem. MSCs, collected from various sources such as bone marrow, teeth
or skin, can be used directly or after expansion, with or without ex vivo gene transfer. MSCs stimulate regulatory T cell (Treg) function
and inhibit all other cell types of the immune system, such as B and T cells, monocytes, immature dendritic cells (iDCs) and classical
dendritic cells (cDCs). Gene transfer of an immunomodulatory or other factor may further enhance the efficacy of MSC therapy.
plasticity and their presence in adult humans make them a very
attractive candidate for clinical use. In addition to bone marrow,
they have been discovered in a number of other tissues such as
brain, skin, skeletal muscle and the gastrointestinal tract (108-
110). They were also found in oral tissues such as dental pulp
and periodontal ligament (111-115). MSCs can be used for the
regeneration of bone, liver, neuronal tissue, blood and skeletal
muscle (111, 112, 116-120). MSCs have the potential to directly
differentiate to multiple lineages of mesenchymal origin,
including bone, cartilage, fat, connective tissue, smooth muscle
and hematopoietic supportive stroma (121).
MSCs of dental origin, including dental pulp stem cells
(DPSCs) and periodontal ligament stem cells (PDLSCs), are of
particular interest. Despite their small size, teeth are an abundant
source of DPSCs and PDLSCs (111, 114, 115). Importantly,
MSCs are normally obtained from teeth removed during routine
dental care. At present, a major focus in our laboratory is to
study the differentiation, regeneration and immunomodulatory
potential of MSCs of dental origin. Since stem cell cultures of
dental origin exhibit mesenchymal stem cell characteristics (111,
114, 115), one of the most plausible directions for differentiation
and potential utilization of these cells is the osteogenic one.
Indeed, in response to appropriate pharmacological induction
MSCs of human dental origin can be induced in vitro to
differentiate into an osteogenic/odontogenic phenotype,
characterized by polarized cell bodies and accumulation of
mineralized nodules (111-116, 122). In this respect it is
important to note that oral MSCs derive from neural crest cells,
whereas bone marrow derived MSCs (BMSCs) originate from
the mesoderm. Therefore, some differences in their behaviour
are predictable (123, 124) as they may be more suitable for
craniofacial regeneration, such as periodontal area
reconstruction, than bone marrow originated MSCs.
IMMUNOMODULATION 
BY MESENCHYMAL STEM CELLS
Importantly, MSCs can escape immune recognition and inhibit
immune response (125) (Fig. 2). Therefore, MSCs are excellent
candidates as immunosuppressive agents during solid-organ
transplantation and to treat graft-vs-host disease, inflammatory
diseases, and other autoimmune diseases (126-128). MSCs exert
their immunomodulatory function via several mechanisms and
acting on various cell types of the immune system.
T-cell suppression by mesenchymal stem cells
One of the major mechanisms of immunosuppression by
MSCs is the effect on T-cells. BMSCs inhibit the proliferation of
T-cells in mixed lymphocyte cultures in vitro (20, 129-131). The
inhibitory effect is independent of antigen presenting cells,
major histocompatibility complex molecules and Treg cells
(130). BMSCs suppress T-cells primarily via the secretion of
soluble factors (132, 133) such as TGFb (129, 134), hepatocyte
growth factor (129), interleukin-10 (135) and prostaglandin E2
(136). In addition, BMSCs inhibit T-cell proliferation by the
secretion of indoleamine 2,3-dioxygenase (IDO), which is
induced by IFN-g (137, 138). The production of nitric oxide
(NO) is also a potential mechanism by which BMSCs inhibit T-
cell proliferation (139).
Induction of regulatory T cells by mesenchymal stem cells
MSCs also modulate immune responses through the
induction of Treg cells. In mitogen-stimulated cultures of
peripheral blood mononuclear cells, MSCs can induce the
generation of CD4+ CD25+ T cells displaying a regulatory
phenotype (136, 140-142). According to a recent study, the
induction of CD4+ CD25+ FoxP3+ Treg cells by MSCs resulted
in increased allograft tolerance in kidney transplant patients
(143). Furthermore, MSCs prevent autoimmune B cell
destruction and subsequent diabetes in NOD mice via the
induction of IL-10 producing Treg cells (144) and induce Treg
cells in a cell contact by a PGE2 and TGF-b1 dependent manner
(145). Additional studies suggest that the effects of MSCs in the
treatment of autoimmune diseases and diabetes may rely on the
induction of de novo generation of Treg cells (146-148), which
then promote regerenation over inflammation.
B cell and natural killer (NK) cell regulation by mesenchymal
stem cells
MSCs can block pathogenic B-cell response in vivo (149).
When B cells and MSCs were cocultured in vitro, humoral
factor(s) released by MSCs suppressed B-cell terminal
differentiation (150) and proliferation (151). However, other
investigators found that MSCs stimulate IgG secretion by B cells
and support their proliferation (152, 153). Therefore, their effect
remains controversial. Natural killer (NK) cells have been
shown to contribute to inflammatory conditions such as
inflammatory bowel disease (154) and periodontitis (155).
BMSCs were reported to suppress proliferation, cytokine
secretion and cytotoxicity of NK cells (136, 142, 156).
Modulation of antigen presenting cells by mesenchymal stem cells
BMSCs were shown to inhibit the differentiation of CD14+
human monocytes into dendritic cells and to revert mature DC
into an immature state with decreased expression of antigen
presentation molecules and costimulatory molecules and
reduced IL-12 secretion via both cell-cell contact and the
secretion of soluble factors (157) (158). BMSCs were reported
to block monocyte differentiation into DCs by preventing their
entry into the G1 phase of the cell cycle (159). The soluble factor
secreted by BMSCs to suppress DC differentiation and
maturation was shown to be PGE2 (160). Furthermore, PGE2
secreted by exogenously administered BMSCs was reported to
reprogram macrophages to produce IL-10 in an experimental
cecal ligation and puncture sepsis model (161). BMSCs were not
only shown to inhibit DC differentiation and maturation, but also
to alter the cytokine secretion profile of DCs and convert them
into a regulatory phenotype (135, 136). In addition,
macrophages co-cultured with MSCs acquired an anti-
inflammatory and wound-healing phenotype and accelerated
wound healing in vivo (162).
In summary, mesenchymal stem cells exhibit their
immunomodulatory effect via several mechanisms: they
suppress the proliferation and function of T cells, stimulate
Treg cells, inhibit the differentiation of dendritic cells and
convert DCs and macrophages into anti-inflammatory
phenotypes (Fig. 2).
IMMUNOMODULATION BY MESENCHYMAL STEM
CELLS OF DENTAL ORIGIN
MSCs of dental origin have also been shown to possess
potent immunomodulatory functions comparable to those of
BMSCs, which make them promising alternative cell sources for
MSC-based therapies (163). Considerable evidence supports that
mesenchymal stem cells of oral origin may be useful therapeutic
agents for immunosuppression not only in oral inflammation but
also in various other chronic inflammatory conditions (18).
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T cell suppression by mesenchymal stem cells of dental origin
DPSCs are able to induce the apoptosis of already activated
T cells in vitro (164). DPSCs were also shown to inhibit the
proliferation of stimulated T cells, and this inhibitory effect was
actually stronger than that of bone marrow derived MSCs (130,
165). The immunosuppressive activity of DPSCs is mediated
most probably at least in part by soluble factors such as TGF-b
(166). Toll-like receptors, which are widely distributed on
immune cells, are able to trigger immunosuppression by DPSCs
through the increased expression of TGF-b and IL-6 (167).
PDLSCs were also shown to suppress T cells (166, 168). In
an animal experimental periodontitis model, PDLSCs cured the
inflammation in part by suppressing the activation of T cells in a
prostaglandin E2-dependent manner (169). Another recent study
has shown that PDLSCs from inflamed periodontal ligament can
inhibit T cell proliferation, Th17 differentiation and IL-17
production (170). Th17 cell activity is also inhibited by stem
cells from human exfoliated deciduous teeth (SHED), even more
efficiently than by BMSCs, an effect that is sufficient to reverse
systemic lupus erithematosus-associated disorders in a mouse
model (171).
MSCs derived from human gingiva (GMSCs) also inhibit T
cell proliferation. This effect is mediated by IFN-g induced
stimulation of IDO, IL-10, COX-2, and inducible nitric oxide
synthase (iNOS) expression (172).
Treg induction by mesenchymal stem cells of dental origin
A recent study has shown induction of CD4+ CD25+
Foxp3+ regulatory T cells and suppression of Th17
differentiation by normal PDLSCs, and this capacity was
present, even though to a lesser extent, in inflamed PDLSCs
(170). Furthermore, MSCs derived from human gingiva
(GMSCs) have been shown to ameliorate inflammation in
experimental colitis by inducing a wide panel of anti-
inflammatory factors and by increased infiltration of Treg cells
to sites of inflammation (172).
In summary, MSCs of dental origin have been reported to
exert immunomodulatory effects by a similar mechanism as
MSCs of other sources (Fig. 2).
ENGINEERED MESENCHYMAL STEM CELLS
IN THE TREATMENT OF PERIODONTITIS
Genetic modification enhances the therapeutic potential of
MSCs (173). MSCs engineered to express IL-10 reduce the
expression of inflammatory cytokines, prevent acute allograft
rejection and promote survival after experimental orthotopic
liver transplantation (174), exert local anti-inflammatory effects
in an ear inflammation model (175), and prevent ischemia-
reperfusion injury after experimental lung transplantation (176).
Since increased osteoclast activity is a key feature of
periodontitis (23), the beneficial effects of MSCs on bone loss,
exerted through their immunmodulatory properties, can be
enhanced by directly influencing the OPG/RANKL balance via
expressing osteoprotegerin in PDLSCs or DPSCs. To this end,
using adenoviral transduction we expressed mouse
osteoprotegerin (mOPG) in human periodontal ligament stem
cells prepared as described before (112). Our data showed that
PDLSCs could be engineered to express transgenic proteins by
transduction with a recombinant serotype 5 adenovirus encoding
either LacZ (AdLacZ) or mOPG (AdmOPG). We found that
AdmOPG transduction of PDLSCs resulted in dose and time
dependent expression of mOPG in cell culture supernatants (Fig.
3B). When we delivered PDLSCs transduced with AdmOPG
systemically into rats by retro-orbital injection, we found that
injection of AdmOPG-transduced but not of AdLacZ-transduced
PDLSCs resulted in mOPG expression in rat sera above
background levels (Fig. 3C). Thus, injection of PDLSCs
engineered by adenoviral transduction can be used for systemic
delivery of therapeutic proteins in vivo. These proof-of-concept
experiments clearly show that human mesenchymal stem cells of
periodontal ligament origin, after transduction by an adenoviral
construct, are able to efficiently deliver therapeutic
osteoprotegerin into experimental animals.
Taken together, mesenchymal stem cells from dental sources
such as the dental pulp, the periodontal ligament and the gingiva,
represent a high, but at present not fully explored potential for
immunomodulation and tissue regeneration not only in
periodontital diseases but also in other inflammatory disorders.
Although this potential is well understood in some aspects, it is
completely unknown in others (18, 19), indicating the need for
more research to speed the path to clinical applications. Also,
besides the immunomodulatory effects, this potential can be
further advanced in the future by possible gene therapy
interventions, either to target destructive osteoclast activity or to
enhance regenerative osteoblast function.
MESENCHYMAL STEM CELLS OF DENTAL ORIGIN
AS BUILDING BLOCKS FOR PERIODONTAL TISSUE
REGENERATION
Mesenchymal stem cells from a number of sources have
been suggested to have high potential for periodontal tissue
regeneration (177). BMSCs were shown to induce periodontal
regeneration of class III furcation defects in dogs (17, 178). GFP
tracing revealed that transplanted BMSCs differentiated into
cementoblasts, osteoblasts, osteocytes, and fibroblasts of the
regenerated tissue. BMSCs induced periodontal regeneration in
human subjects as well (179).
Adipose-derived mesenchymal stem cells
(ASCs) were also observed to be capable of osteogenic
(180), as well as condrogenic and myogenic (181, 182)
differentiation. ASCs mixed with platelet-rich plasma facilitated
alveolar bone regeneration and the formation of a periodontal
ligament-like structure in rat periodontal tissue defects (183).
Among the different cellular sources PDLSCs have been
reported to be useful for the treatment of periodontal
inflammation and bone loss due to their regenerative effects in
an experimental porcine model of periodontitis (184).
Periodontal lesions were created by the surgical removal of
bone mesially to the first molars in miniature pigs (184).
Autologous stem cells were isolated from the periodontal
ligament of cuspids, expanded ex vivo, loaded on HA/TCP
scaffolds, and transplanted into the bone defects. Twelve weeks
later, bone regeneration was significantly improved and
inflammatory cell infiltration was reduced in PDLSC-HA/TCP
treated pigs compared to the control and HA/TCP only treated
groups (184). By tracing transplanted PDLSCs using a
retroviral vector encoding green fluorescent protein, it was
shown that GFP-labeled cells were present in newly formed
periodontal bones and differentiated into osteoblasts (184).
Feng and coworkers also demonstrated the utility of
transplanted autologous PDL progenitors, a cell population
highly similar to PDLSCs, for periodontal regeneration in
human patients (185). Similar results were obtained with human
PDLSCs by another group in rats (186).
Most previous studies aimed to prepare stem cells of
periodontal origin from normal human tissues (112, 114-116,
332
122). However, a recent work clearly showed that PDLSCs may
also be isolated from patients suffering from chronic
periodontitis with a severe degree of inflammation. This work
demonstrated that stem cells can be easily isolated from
granulation tissue being extracted during minimally-invasive
periodontal surgery (187). Their full capacity to differentiate into
both osteogenic and neuronal lineages, just like PDLSCs
isolated from uninflamed periodontium, was also shown (187).
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Fig. 3. Osteoprotegerin is effectively expressed in mesenchymal stem cells of dental origin,, the in vivo delivery of transduced cells
elevates plasma osteoprotegerin level in rats. Ex vivo gene transfer of periodontal ligament stem cells (PDLSCs) using adenoviral
vectors. (A) Demonstration of AdLacZ transduction of PDLSCs. Cells were transduced with AdLacZ at different viral particles (vp)
per cell ratios (1–3: 100 vp/cell; 4–6: 5000 vp/cell) for various durations (1, 4: 0 day; 2, 5: 1 day; 3, 6: 4 days). Cells were stained for
b-galactosidase. (B) mOPG production by PDLSCs after in vitro transduction. PDLSCs were transduced with either AdLacZ (symbols
rhombus, t and line, –) or AdmOPG (symbols square, n and circle, l) at the indicated vp/cell ratios and for the durations of 1 day
(symbols rhombus, t and square, n) or 4 days (symbols line, – and circle, l). mOPG concentrations determined by ELISA kit from
supernatants. (C) PDLSC-mediated adenoviral gene therapy for systemic production of mOPG in rats in vivo. PDLSCs transduced ex
vivo with either AdLacZ or AdmOPG at 5000 vp/cell, were injected retro-orbitally to rats (4.3×106 cells/animal). Sera were collected
after 2 days and 7 days as indicated and mOPG concentrations were measured by ELISA. AdLacZ was purchased from the Vector
Development Laboratory at the Baylor College of Medicine. AdmOPG was prepared at our laboratory.
Fig. 4. Adenoviral infection of mesenchymal stem cells of dental origin is an efficient way to transduce BMP-2. The graph shows
production of BMP-2 by dental pulp stem cells (DPSCs) after adenoviral transduction. DPSCs were transduced by either AdLacZ or
AdBMP-2, at different vp/cell ratios (MOI) and for different durations as indicated, supernatant media were collected, and BMP-2
concentrations determined by ELISA kit. AdBMP-2 was a generous gift from Dr. Elizabeth A. Davis, Baylor College of Medicine.
When these PDLSC cells obtained from inflamed human
periodontium were layered onto collagen sponges and implanted
into periodontal defects on the right buccal cortex of the
mandible of immunodeficient nude rats, accelerated reformation
of periodontal ligament-like tissue, collagen fibers and elements
of bone were found indicating partial but not full regeneration
(188). These results are very similar to those obtained by using
PDLSCs isolated from non-inflamed human periodontal tissue,
then implanted into the experimentally created periodontal
defects in rats (189) and in minipigs (184). Collectively, these
data support the notion that periodontal progenitors isolated
either from normal or from inflamed periodontium are able to
promote periodontal wound healing. This is extremely important
since in the future it might become possible to isolate
periodontal stem cells from the inflamed area which needs
treatment anyway, in order to cultivate, enrich and possibly
genetically modify the cells for subsequent reimplantation into
the inflamed area to achieve tissue regeneration.
In the context of tissue regeneration, it is of note that MSCs
were first identified as a cell population in the bone marrow that
can make bone and reconstitute a hematopoietic
microenvironment (190) and they can give rise to, among other
cell types, osteoblasts (121). Osteoblasts are the cells that produce
new bone. They are important sources of RANKL and M-CSF for
the development of osteoclasts (40). They also produce bone
morphogenetic proteins, including BMP-2, which plays a major
role in the differentiation of bone cell lineages, bone development
and bone repair (39), and is approved for human clinical use in
orthopedic surgery (16). Therefore, genetic engineering of MSCs
to express BMP-2 should enhance their therapeutic effect in bone
regeneration. Indeed, MSCs expressing transgenic BMP2 (or
VEGF) accelerate bone healing when co-implanted into critical-
sized bone defects (191). Furthermore, PDLSCs transduced with
AdBMP-2 had better osteogenic potential than PDLSCs alone or
treated with recombinant BMP-2 (192). In another study, MSCs
transduced with AdBMP-2 mediated regeneration of alveolar
bone defects better than MSCs alone (193). These results show
that genetic engineering of MSCs, including those of dental origin,
to express BMP-2 enhances their osteoblastogenic potential and
thereby promotes bone regeneration.
Our own results also show that human MSCs of dental origin,
namely DPSCs, can be engineered by adenoviral transduction to
express BMP-2. We transduced DPSCs with either AdLacZ or
AdBMP2 at 3000 or 10000 particles/cell and measured BMP-2
concentration in media supernatants after 1, 3 and 7 days. We
found that AdBMP-2 but not AdLacZ transduction lead to BMP-
2 production by human DPSCs in a dose and time dependent
manner (Fig. 4). Importantly, transduction with either AdLacZ or
AdBMP-2 had no substantial effect on the viability of DPSCs at
either dose or time point. These proof-of-concept results are in
line with the available literature data described above. These data
further confirm that, in addition to unmodified mesenchymal
stem cells utilized in the future as building blocks for periodontal
regeneration, genetically engineered MSCs of dental or other
origin may also be used. This will exploit the fact that they
produce therapeutic proteins that will increase their efficacy of
tissue reconstructing capacity.
CONCLUDING REMARKS
Conventional treatments including the removal of bacterial
deposit, surgical tissue regeneration procedures and enhanced oral
hygiene may not be satisfactory to prevent, to slow down or to
stop periodontitis. Such interventions are usually insufficient to
promote the regeneration of damaged structures. The use of
mesenchymal stem cells to treat inflammatory diseases such as
periodontitis is an emerging area of interest. Importantly, MSCs
can be obtained from a variety of sources such as bone marrow,
skin or teeth, and they can be expanded ex vivo to generate a
sufficient number of cells. The therapeutic effects of allogeneic or
autologous MSCs can be primarily attributed to their
immunomodulatory effects. As it appears, their immunoregulatory
function can be augmented by genetic modification. Genetically
engineered mesenchymal stem cells offer multiple ways to target
periodontal disease: in addition to the potent immunomodulatory
effect, they may inhibit bone loss or promote bone regeneration,
respectively. Thus, engineered mesenchymal stem cells from
sources such as the dental pulp and the periodontal ligament
represent a high, but at present not fully explored potential for
immunomodulation and bone regeneration in periodontotal
diseases.
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